Cargando…
Potential of Ferritin-Based Platforms for Tumor Immunotherapy
Ferritin is an iron storage protein that plays a key role in iron homeostasis and cellular antioxidant activity. Ferritin has many advantages as a tumor immunotherapy platform, including a small particle size that allows for penetration into tumor-draining lymph nodes or tumor tissue, a unique struc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104857/ https://www.ncbi.nlm.nih.gov/pubmed/35566065 http://dx.doi.org/10.3390/molecules27092716 |
_version_ | 1784707897152765952 |
---|---|
author | Xu, Xiaoling Tian, Kewei Lou, Xuefang Du, Yongzhong |
author_facet | Xu, Xiaoling Tian, Kewei Lou, Xuefang Du, Yongzhong |
author_sort | Xu, Xiaoling |
collection | PubMed |
description | Ferritin is an iron storage protein that plays a key role in iron homeostasis and cellular antioxidant activity. Ferritin has many advantages as a tumor immunotherapy platform, including a small particle size that allows for penetration into tumor-draining lymph nodes or tumor tissue, a unique structure consisting of 24 self-assembled subunits, cavities that can encapsulate drugs, natural targeting functions, and a modifiable outer surface. In this review, we summarize related research applying ferritin as a tumor immune vaccine or a nanocarrier for immunomodulator drugs based on different targeting mechanisms (including dendritic cells, tumor-associated macrophages, tumor-associated fibroblasts, and tumor cells). In addition, a ferritin-based tumor vaccine expected to protect against a wide range of coronaviruses by targeting multiple variants of SARS-CoV-2 has entered phase I clinical trials, and its efficacy is described in this review. Although ferritin is already on the road to transformation, there are still many difficulties to overcome. Therefore, three barriers (drug loading, modification sites, and animal models) are also discussed in this paper. Notwithstanding, the ferritin-based nanoplatform has great potential for tumor immunotherapy, with greater possibility of clinical transformation. |
format | Online Article Text |
id | pubmed-9104857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91048572022-05-14 Potential of Ferritin-Based Platforms for Tumor Immunotherapy Xu, Xiaoling Tian, Kewei Lou, Xuefang Du, Yongzhong Molecules Review Ferritin is an iron storage protein that plays a key role in iron homeostasis and cellular antioxidant activity. Ferritin has many advantages as a tumor immunotherapy platform, including a small particle size that allows for penetration into tumor-draining lymph nodes or tumor tissue, a unique structure consisting of 24 self-assembled subunits, cavities that can encapsulate drugs, natural targeting functions, and a modifiable outer surface. In this review, we summarize related research applying ferritin as a tumor immune vaccine or a nanocarrier for immunomodulator drugs based on different targeting mechanisms (including dendritic cells, tumor-associated macrophages, tumor-associated fibroblasts, and tumor cells). In addition, a ferritin-based tumor vaccine expected to protect against a wide range of coronaviruses by targeting multiple variants of SARS-CoV-2 has entered phase I clinical trials, and its efficacy is described in this review. Although ferritin is already on the road to transformation, there are still many difficulties to overcome. Therefore, three barriers (drug loading, modification sites, and animal models) are also discussed in this paper. Notwithstanding, the ferritin-based nanoplatform has great potential for tumor immunotherapy, with greater possibility of clinical transformation. MDPI 2022-04-22 /pmc/articles/PMC9104857/ /pubmed/35566065 http://dx.doi.org/10.3390/molecules27092716 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Xu, Xiaoling Tian, Kewei Lou, Xuefang Du, Yongzhong Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title | Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title_full | Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title_fullStr | Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title_full_unstemmed | Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title_short | Potential of Ferritin-Based Platforms for Tumor Immunotherapy |
title_sort | potential of ferritin-based platforms for tumor immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104857/ https://www.ncbi.nlm.nih.gov/pubmed/35566065 http://dx.doi.org/10.3390/molecules27092716 |
work_keys_str_mv | AT xuxiaoling potentialofferritinbasedplatformsfortumorimmunotherapy AT tiankewei potentialofferritinbasedplatformsfortumorimmunotherapy AT louxuefang potentialofferritinbasedplatformsfortumorimmunotherapy AT duyongzhong potentialofferritinbasedplatformsfortumorimmunotherapy |